Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ProAssurance ( (PRA) ) has issued an update.
On March 19, 2025, ProAssurance announced a merger agreement with The Doctors Company, where ProAssurance will become a wholly owned subsidiary. The merger includes provisions for executive compensation adjustments to mitigate tax impacts, reflecting the company’s strategic alignment with its performance targets for 2025.
The most recent analyst rating on (PRA) stock is a Hold with a $24.50 price target. To see the full list of analyst forecasts on ProAssurance stock, see the PRA Stock Forecast page.
Spark’s Take on PRA Stock
According to Spark, TipRanks’ AI Analyst, PRA is a Neutral.
ProAssurance’s overall score is primarily influenced by its financial performance, which shows significant challenges in revenue growth and cash flow management. The technical analysis suggests a neutral market sentiment, while the valuation indicates the stock is relatively expensive. The strong balance sheet provides some stability, but improvements in cash flow and operational efficiency are crucial for future growth.
To see Spark’s full report on PRA stock, click here.
More about ProAssurance
ProAssurance is involved in the insurance industry, focusing on providing medical professional liability insurance and other related products. The company has a market focus on healthcare providers and institutions, offering risk management and insurance solutions.
Average Trading Volume: 369,797
Technical Sentiment Signal: Buy
Current Market Cap: $1.23B
For a thorough assessment of PRA stock, go to TipRanks’ Stock Analysis page.